Value of long non-coding RNA HAS2-AS1 as a diagnostic and prognostic marker of glioma

A You; J Gu; J Wang; J Li; Y Zhang; G Rao; X Ge; K Zhang; X Gao; D Wang

doi:10.1016/j.nrleng.2021.06.008

Value of long non-coding RNA HAS2-AS1 as a diagnostic and prognostic marker of glioma

Neurologia (Engl Ed). 2024 May;39(4):353-360. doi: 10.1016/j.nrleng.2021.06.008.

Authors

A You¹, J Gu¹, J Wang¹, J Li¹, Y Zhang¹, G Rao¹, X Ge¹, K Zhang¹, X Gao², D Wang³

Affiliations

¹ The Fourth Department of Neurosurgery, Tangshan Gongren Hospital, 063000 Tangshan, China.
² Operating Theatre, Tangshan Central Hospital, 063000 Tangshan, China.
³ The Fourth Department of Neurosurgery, Tangshan Gongren Hospital, 063000 Tangshan, China. Electronic address: docwangdc1981@163.com.

PMID: 38616063
DOI: 10.1016/j.nrleng.2021.06.008

Abstract

Background: Glioma presents high incidence and poor prognosis, and therefore more effective treatments are needed. Studies have confirmed that long non-coding RNAs (lncRNAs) basically regulate various human diseases including glioma. It has been theorized that HAS2-AS1 serves as an lncRNA to exert an oncogenic role in varying cancers. This study aimed to assess the value of lncRNA HAS2-AS1 as a diagnostic and prognostic marker for glioma.

Methods: The miRNA expression data and clinical data of glioma were downloaded from the TCGA database for differential analysis and survival analysis. In addition, pathological specimens and specimens of adjacent normal tissue from 80 patients with glioma were used to observe the expression of HAS2-AS1. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic ability and prognostic value of HAS2-AS1 in glioma. Meanwhile, a Kaplan-Meier survival curve was plotted to evaluate the survival of glioma patients with different HAS2-AS1 expression levels.

Results: HAS2-AS1 was significantly upregulated in glioma tissues compared with normal tissue. The survival curves showed that overexpression of HAS2-AS1 was associated with poor overall survival (OS) and progression-free survival (PFS). Several clinicopathological factors of glioma patients, including tumor size and WHO grade, were significantly correlated with HAS2-AS1 expression in tissues. The ROC curve showed an area under the curve (AUC) value of 0.863, indicating that HAS2-AS1 had good diagnostic value. The ROC curve for the predicted OS showed an AUC of 0.906, while the ROC curve for predicted PFS showed an AUC of 0.88. Both suggested that overexpression of HAS2-AS1 was associated with poor prognosis.

Conclusions: Normal tissues could be clearly distinguished from glioma tissues based on HAS2-AS1 expression. Moreover, overexpression of HAS2-AS1 indicated poor prognosis in glioma patients. Therefore, HAS2-AS1 could be used as a diagnostic and prognostic marker for glioma.

Keywords: ARNncl HAS2-AS1; Biomarcador; Biomarker; Glioma; lncRNA HAS2-AS1.

MeSH terms

Glioma* / diagnosis
Glioma* / genetics
Humans
Hyaluronan Synthases
Prognosis
RNA, Long Noncoding* / genetics
ROC Curve

Substances

Hyaluronan Synthases
RNA, Long Noncoding